tiprankstipranks
Blurbs

Maxim Group Sticks to Its Buy Rating for Longeveron (LGVN)

In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on Longeveron (LGVNResearch Report), with a price target of $14.00. The company’s shares opened today at $3.52.

Okunewitch covers the Healthcare sector, focusing on stocks such as Mediwound, Kiora Pharmaceuticals, and Citius Pharmaceuticals. According to TipRanks, Okunewitch has an average return of -30.3% and a 19.35% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Longeveron with a $13.25 average price target, which is a 276.42% upside from current levels. In a report released on January 10, EF Hutton also maintained a Buy rating on the stock with a $12.50 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $16.77 and a one-year low of $2.80. Currently, Longeveron has an average volume of 75.57K.

Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LGVN in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Longeveron LLC is a biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. It is involved in sponsoring clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS).

Read More on LGVN:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles